Skip to main content
  •   Home
  •   Download
  •   Manual
  •   Contact

Drug Combination Details

General Information of the Combination (ID: C40727)
Name Paclitaxel   NP Info  + Cisplatin   Drug Info 
Structure +
Disease
Ovarian cancer [ICD-11: 2C73]
Phase 3 [1]
Colorectal cancer [ICD-11: 2B91]
Investigative [2]
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally
    α. Enhancing Drug Efficacy by This Combination
                 Achieving Therapeutic Synergy     Click to Show/Hide
                    Experiment 1 Reporting the Effect of This Combination [2]
                    In-vitro Model LoVo CVCL_0399 Colon adenocarcinoma Homo sapiens
                    Experimental
                    Result(s)
Paclitaxel in combination with cisplatin showed the most cytotoxic effect in colorectal cancer cells.
References
Reference 1 ClinicalTrials.gov (NCT00002717) Paclitaxel and Cisplatin in Treating Patients With Stage III or Stage IV Ovarian Cancer or Primary Peritoneal Cancer.
Reference 2 Cytotoxicity of paclitaxel in combination with cisplatin and a new Pt-mercaptopyridine complex. Anticancer Res. Sep-Oct 2002;22(5):2783-8.
 Download Picture         KEGG Link      
Cite NPCDR
Visitor Map
Correspondence

X. N. Sun, Y. T. Zhang, Y. Zhou, X. C. Lian, L. L. Yan, T. Pan, T. Jin, H. Xie, Z. M. Liang, W. Q. Qiu, J. X. Wang, Z. R. Li, F. Zhu*, X. B. Sui*. NPCDR: natural product-based drug combination and its disease-specific molecular regulation. Nucleic Acids Research. 50(D1): 1324-1333 (2020). PMID: 34664659

Prof. Feng ZHU  (zhufeng@zju.edu.cn)

College of Pharmaceutical Sciences, Zhejiang University, Hangzhou, China


Prof. Xinbing SUI  (hzzju@hznu.edu.cn)

School of Pharmacy and Department of Medical Oncology, the Affiliated Hospital of Hangzhou Normal University, Hangzhou Normal University, Hangzhou, China